Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance

Xeris Biopharma Holdings, Inc.

2023-FY EPS reported -$0.12 revenue$33,196,000

Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.
Net loss $16.8M ($0.12 per share); cash & investments $95.1M at March 31, 2023.
2023 guidance: revenue $135M-$165M; cash from ops ($57M)-($77M); year-end cash $45M-$65M.
Announced XeriJect collaboration with Regeneron for two undisclosed monoclonal antibodies.
Appointed Ricki Fairley to Board of Directors, increasing board to nine members.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $33.2M, net income $16.8 million, EPS $0.12 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $33.2M
Net income: $16.8 million
EPS: $0.12 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M;

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.